secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001411690-23-000067
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Genomics Q2 revenue up 30% to $8.7M; flowcell sales more than double YoY
--------------------------------------------------------------------------------

- Q2 2023 revenue $8.7M, +30% YoY; GAAP gross margin 27% vs 22%.
- Installed Saphyr systems 281 (+43% YoY); flowcells sold 7,062 (+108% YoY).
- GAAP operating expense $41.5M vs $33.6M; non-GAAP opEx $34.6M.
- Cash & securities $77.1M at June 30, down from $95.8M at March 31.
- Announced Stratys high-throughput OGM system and VIA software for hematologic malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169023000067/0001411690-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169023000067/bngo-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001411690-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer